INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Hyphenated Analytical Techniques in Pharmaceutical Analysis: Principles, Instrumentation and Applications

Arunlal V.B.*, Layana Valsan

Department of Pharmaceutical Analysis, National College of Pharmacy

ARTICLE INFO

Published: 3 Jun. 2026

Keywords:
Hyphenated techniques, pharmaceutical analysis, LC-MS, GC-MS, HPLC-DAD, LC-NMR, CE-MS, TGA-MS, impurity profiling, bioanalysis, stability-indicating methods, chiral separation, drug quality control

DOI:
10.5281/zenodo.20526442

ABSTRACT

Hyphenated analytical techniques combine chromatographic or electrophoretic separation methods with spectroscopic or spectrometric detectors to achieve highly sensitive and selective pharmaceutical analysis. This review discusses the principles, instrumentation, and pharmaceutical applications of major hyphenated techniques such as LC-MS, LC-MS/MS, GC-MS, HPLC-DAD, LC-NMR, CE-MS, and TGA-MS. A comprehensive literature review of peer-reviewed studies published between 2010 and 2025 was conducted using PubMed, Scopus, Web of Science, and ScienceDirect databases. The study focused on applications in impurity profiling, bioanalysis, metabolite identification, stability studies, and pharmaceutical quality control. The review highlights LC-MS and LC-MS/MS as the most widely used techniques for impurity profiling and bioanalytical studies due to their high sensitivity and specificity. GC-MS remains important for volatile compound and residue analysis, while HPLC-DAD provides cost-effective stability-indicating analysis. LC-NMR offers superior structural elucidation of unknown compounds, and CE-MS is effective for chiral separations with minimal sample usage. Thermal hyphenated methods such as TGA-MS are valuable for solid-state characterization. Overall, hyphenated techniques play a crucial role in drug discovery, development, manufacturing, and regulatory compliance. Future advancements are expected in miniaturized systems, ambient ionization MS, and AI-assisted data interpretation, which will further enhance pharmaceutical analysis.

INTRODUCTION

Modern pharmaceutical analysis stands at the crossroads of stringent regulatory demands, ever-increasing molecular complexity, and the imperative to detect analytes at ever lower concentration thresholds. The global pharmaceutical market, valued at over USD 1.4 trillion in 2023 and projected to exceed USD 1.9 trillion by 2028, depends critically on robust

---

***Corresponding Author:** Arunlal V.B
Address: *National College of Pharmacy*
Email ✉: arunlalvb@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

analytical methodologies to ensure the safety, quality, and efficacy of drug substances and drug products.[1] Regulatory agencies—including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the International Council for Harmonisation (ICH)—impose rigorous specifications for impurity limits, residual solvents, dissolution profiles, and pharmacokinetic bioequivalence that challenge single-technique approaches.

Historically, pharmaceutical analysis relied on individual techniques such as ultraviolet-visible (UV-Vis) spectrophotometry, classical high-performance liquid chromatography (HPLC) with UV detection, gas chromatography (GC) with flame ionization detection (FID), and titration-based assays. While these methods remain valuable for routine quality control, they are often insufficient when dealing with structurally similar degradation products, trace genotoxic impurities at ICH M7 thresholds of 1.5 µg/day, or complex biological matrices containing thousands of endogenous interferences. The inadequacy of standalone techniques in such scenarios catalysed the development of hyphenated analytical systems.

The concept of hyphenated techniques in analytical chemistry was formally introduced by Hirschfeld in 1980, who described it as the 'marriage' of two or more analytical instruments via an appropriate interface, enabling on-line separation and detection. Since that pioneering conceptualization, the field has grown enormously. The term 'hyphenated' reflects the typographical hyphen used to denote the combination—e.g., GC-MS, LC-MS, HPLC-NMR—and by extension signifies a philosophy of synergy wherein the combined system produces analytical information of a quality and breadth that neither technique alone could provide.

Hyphenated techniques can be broadly classified into three categories based on the nature of the coupled techniques: (i) separation-detection hyphenation (e.g., LC-MS, GC-MS, HPLC-DAD); (ii) separation-separation hyphenation, also called multidimensional chromatography (e.g., LC×LC, GC×GC); and (iii) detection-detection hyphenation (e.g., MS-MS, NMR-MS). In pharmaceutical analysis, the most widely exploited category remains separation-detection hyphenation, particularly combinations involving mass spectrometry, which provides universal detection, molecular mass information, and structural fragmentation data.

The practical advantages of hyphenated techniques over standalone methods are manifold. They provide simultaneous separation and identification, dramatically reduce analysis time and sample consumption, minimize sample handling artefacts through closed-system operation, offer enhanced sensitivity and selectivity through specific detection, and generate multidimensional structural data that facilitates unambiguous compound identification. They also reduce or eliminate the need for reference standards in structural elucidation, which is a significant advantage during early drug development when authentic impurity standards may be unavailable.[2]

This review comprehensively examines the principles, instrumentation, and pharmaceutical applications of the principal hyphenated techniques—LC-MS, LC-MS/MS, GC-MS, GC-MS/MS, HPLC-DAD, LC-NMR, CE-MS, TGA-MS, and multidimensional platforms—while addressing their regulatory context, comparative advantages, limitations, and emerging future directions. The coverage extends from foundational physicochemical principles through state-of-the-art instrumentation to concrete pharmaceutical applications across drug discovery, impurity profiling, bioanalysis, stability testing, and quality control.

CLASSIFICATION AND THEORETICAL FOUNDATIONS OF HYPHENATED TECHNIQUES

Separation-Based Systems: Overview

The first component of any hyphenated separation-detection system is the separation engine. In liquid-phase systems, this is most commonly reversed-phase HPLC or ultra-high-performance liquid chromatography (UHPLC) employing C18 or C8 stationary phases. UHPLC instruments operating at pressures up to 15,000 psi with sub-2-µm particles dramatically reduce analysis time while improving peak efficiency ($N > 100,000$ theoretical plates). In gas-phase systems, packed or capillary GC columns offer excellent resolution for volatile and semi-volatile analytes. Capillary electrophoresis (CE) provides separation based on electrophoretic mobility and offers exceptional efficiency ($N > 500,000$ theoretical plates) with minimal sample (nanolitre to microlitre) and reagent consumption.

The efficiency of separation directly determines the quality of subsequent detection. Broad, poorly resolved chromatographic peaks introduce co-elution artefacts, ion suppression in MS, and spectral overlap in NMR. Therefore, method development in hyphenated techniques begins with optimizing the chromatographic or electrophoretic resolution prior to detector-specific optimization.

Detection Modalities and Interfaces

The detector in a hyphenated system must receive the analyte in a form compatible with its operating principle. This requirement creates the primary engineering challenge: the interface. In LC-MS, the high-flow liquid mobile phase must be volatilized and transferred to the high-vacuum mass spectrometer without compromising analyte integrity or ionization efficiency. Atmospheric pressure ionization (API) interfaces—including electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), and atmospheric pressure photoionization (APPI)—have been the transformative solutions enabling routine LC-MS coupling. In GC-MS, the interface problem is less acute because GC already operates with gaseous analytes; jet separators or direct capillary couplings efficiently transfer analytes into the ion source under appropriate pressure differentials.

For LC-NMR coupling, the challenge is different: NMR is inherently insensitive compared to MS, and the protonated solvent signals in common HPLC mobile phases (acetonitrile, methanol, water) overwhelm analyte signals unless elaborate solvent suppression schemes or deuterated solvents are employed. Three principal LC-NMR operating modes—on-flow, stop-flow, and loop-storage—each represent specific technical compromises among throughput, sensitivity, and spectral quality.[3]

Classification Framework

Table 1 provides a structured classification of the major hyphenated analytical techniques used in pharmaceutical analysis, summarizing the separation mechanism, detection principle, typical interface, primary application domains, and key performance parameters.

Table 1. Classification of Major Hyphenated Analytical Techniques in Pharmaceutical Analysis

Technique	Separation Principle	Detection Principle	Key Interface	Primary Application	Typical LOD
LC-MS	RPLC / HILIC	ESI-MS / APCI-MS	ESI, APCI interface	Impurity profiling, metabolites	pg/mL–ng/mL
LC-MS/MS	RPLC / HILIC	Triple quadrupole MS	ESI interface	Bioanalysis, TDM, PK studies	fg/mL–pg/mL
GC-MS	Capillary GC	EI / CI mass spectrometry	Direct capillary inlet	Residual solvents, volatiles	ng/mL–µg/mL
HPLC-DAD	RPLC / NP-LC	UV-Vis diode array	Inline flow cell	Stability studies, assay	ng/mL–µg/mL
LC-NMR	RPLC / HILIC	^{1}H / ^{13}C NMR	Flow probe / SPE-NMR	Structure elucidation, natural products	µg–mg
CE-MS	CZE / MEKC / ITP	ESI-MS	Sheath-liquid interface	Chiral analysis, biologics	nM range
TGA-MS	None (thermal)	Quadrupole MS	Heated capillary line	Thermal decomposition	ppm (gas phase)
GC×GC-MS	2D capillary GC	TOF-MS / Q-MS	Cryogenic modulator	Complex mixtures, volatolomics	pg/mL
UHPLC-HRMS	UHPLC sub-2µm	Orbitrap / Q-TOF	ESI interface	Unknown ID, metabolomics	fg/mL

RPLC = reversed-phase LC; HILIC = hydrophilic interaction chromatography; EI = electron ionization; CI = chemical ionization; CZE = capillary zone electrophoresis; MEKC = micellar electrokinetic chromatography; ITP = isotachophoresis; TOF = time-of-flight; TDM = therapeutic drug monitoring; PK = pharmacokinetic; LOD = limit of detection.

LIQUID CHROMATOGRAPHY–MASS SPECTROMETRY (LC-MS AND LC-MS/MS)

Principles and Ionization Strategies

Liquid chromatography–mass spectrometry (LC-MS) integrates the high-resolution separation capability of HPLC with the detection sensitivity and structural identification power of mass spectrometry. The fundamentals of the mass spectrometer rest on three sequential processes: ionization of the analyte, mass analysis (separation of ions by mass-to-charge ratio, m/z), and detection of the separated ions. In pharmaceutical applications, the soft ionization techniques electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) predominate because they generate intact molecular ions $[M+H]^+$ or $[M-H]^-$ that permit direct molecular weight determination without extensive fragmentation.[4]

In ESI, the liquid eluent is passed through a capillary needle maintained at a high voltage (2–5 kV). The electric field disperses the liquid into a fine spray of charged droplets. Solvent evaporation, assisted by a heated drying gas (typically nitrogen), progressively concentrates charges on the droplet surface. When the electrostatic repulsion overcomes the surface tension—the Rayleigh limit—the droplet undergoes Coulombic fission, ultimately releasing desolvated multiply-charged ions. ESI is particularly effective for high-molecular-weight, polar molecules including peptides, proteins, oligonucleotides, and many pharmaceutical compounds. APCI, conversely, employs a heated nebulizer to rapidly volatilize the mobile phase and a corona discharge needle to ionize the analyte via gas-phase ion-molecule reactions. APCI excels for less polar, lower-molecular-weight analytes that are thermally stable.

Atmospheric pressure photoionization (APPI), introduced more recently, uses photons from a krypton lamp (10.0 eV) to ionize analytes with low proton affinity or those poorly ionized by ESI/APCI. APPI offers complementarity in lipid, polyaromatic hydrocarbon, and vitamin D metabolite analysis. Matrix-assisted laser desorption/ionization (MALDI), although not strictly an LC-coupled online technique in the conventional sense, is widely used for peptide mapping and proteomics via LC-MALDI workflows.

Mass Analyzers Used in Pharmaceutical LC-MS

The choice of mass analyzer profoundly determines the analytical capabilities of an LC-MS system. The triple quadrupole (QqQ) analyzer, consisting of two mass-resolving quadrupoles separated by a collision cell, dominates quantitative pharmaceutical bioanalysis. Its selected reaction monitoring (SRM) or multiple reaction monitoring (MRM) mode achieves exquisite selectivity by monitoring a specific precursor ion (Q1) fragmented to a specific product ion (Q3), eliminating chemical background noise and enabling femtogram-level detection in plasma matrices. This is fundamental to LC-MS/MS pharmacokinetic studies.

High-resolution mass spectrometry (HRMS) platforms—particularly Orbitrap and quadrupole time-of-flight (Q-TOF) analyzers—provide mass accuracies of <5 ppm or even <2 ppm. Orbitrap analyzers, introduced commercially by Thermo Scientific in 2005, measure ion oscillation frequencies in an electrostatic field and achieve resolving powers of 60,000–500,000 (full width at half maximum, FWHM). This ultra-high resolution allows unambiguous molecular formula assignment, dramatically facilitating the identification of unknown degradation products and metabolites without need for authentic reference standards.[5] Q-TOF systems combine a quadrupole mass filter with a time-of-flight analyzer, enabling both targeted MRM-like acquisition and high-resolution full-scan spectra within a single analytical run.

Ion trap analyzers (3D ion trap, linear ion trap) allow multistage fragmentation (MSn, $n \geq 3$) that generates fragment ladders facilitating complete de novo structural characterization of unknowns. Ion mobility spectrometry (IMS) integrated with MS platforms—producing IM-MS systems—adds a gas-phase ion separation dimension based on collisional cross-section, enabling differentiation of isomeric and isobaric compounds that are otherwise chromatographically co-eluting and mass-spectrometrically inseparable.

Pharmaceutical Applications of LC-MS

Impurity Profiling

Regulatory guidelines, particularly ICH Q3A (impurities in new drug substances), ICH Q3B (impurities in new drug products), and ICH M7 (genotoxic impurities), mandate rigorous characterization of pharmaceutical impurities at thresholds as low as 0.05% or 1.5 µg/day lifetime daily intake for potentially mutagenic impurities. LC-MS is the preeminent technique for this application because it provides simultaneous structural identification and quantification of known and unknown impurities within a single analytical run.

By integrating the separation power of liquid chromatography with the detection capabilities of mass spectrometry, LC-MS serves as a crucial technique for both identifying and quantifying impurities in pharmaceuticals. Modern LC-MS systems equipped with high-resolution mass analyzers, tandem MS capabilities, and advanced data processing software serve as indispensable tools for accurate impurity detection, quantification, and structural analysis, ensuring regulatory compliance and safeguarding drug quality and patient safety. For example, high-resolution instruments such as Orbitrap or FT-ICR can achieve resolving powers exceeding 100,000, allowing researchers to distinguish compounds with very close molecular weights including isomers or isotopic impurities and to rapidly identify impurities related to the drug scaffold within complex matrices.

A study by Rambhad and colleagues published in Separation Science Plus (2025) systematically reviewed the use of advanced LC-MS techniques for efficient impurity profiling in drug substances and products, highlighting the technique's capability to detect a broad spectrum of contaminants—inorganic, residual solvents, and synthesis by-products—emphasizing the critical role of comprehensive impurity analysis in ensuring pharmaceutical quality and safety.

Genotoxic N-nitrosamine impurities have attracted intense regulatory attention following the 2018-2020 recalls of sartan and ranitidine medicines. LC-MS/MS methods, employing highly selective MRM transitions, have been at the forefront of nitrosamine detection and quantification at the sub-ppb level. A recent study (2025) described validated LC-MS/MS methods for the simultaneous determination of nitrosamine drug substance-related impurities (NDSRIs) derived from nortriptyline and sertraline, highlighting the technique's superior selectivity in complex pharmaceutical matrices.[6]

Stability-Indicating Methods and Forced Degradation Studies

ICH Q1A(R2) guidelines require pharmaceutical companies to establish the intrinsic stability of drug substances and products through forced degradation (stress testing) under hydrolytic, oxidative, photolytic, and thermal conditions. The resulting degradation products must be characterized and quantified. UHPLC-DAD-MS/MS methods, combining the high chromatographic efficiency of UHPLC with DAD peak purity confirmation and MS/MS structural characterization, have become the preferred approach for this purpose.

A comprehensive study published in 2025 described a validated stability-indicating UHPLC-DAD-MS/MS method for ritlecitinib—a novel JAK3 inhibitor approved for alopecia areata—demonstrating high specificity, sensitivity (LOD: 0.04 µg/mL; LOQ: 0.14 µg/mL), precision (RSD ≤ 0.15%), and accuracy (99.9–100.3%), successfully separating and identifying four degradation products formed under ICH-prescribed stress conditions.[7]

Bioanalysis and Pharmacokinetic Studies

Quantitative bioanalysis of drugs and their metabolites in biological matrices (plasma, serum, urine, dried blood spots) is the backbone of pharmacokinetic (PK) and pharmacodynamic (PD) studies, therapeutic drug monitoring (TDM), and drug-drug interaction investigations. LC-MS/MS in MRM mode represents the gold standard for this application, offering femtogram-level sensitivity with high specificity that enables clean quantification of drug analytes even in the complex biological matrix background.

A comprehensive clinical application review published in Frontiers in Analytical Science (2024) covering studies from 2005 to 2020 confirmed that hyphenated techniques—particularly HPLC-MS, HPLC-MS/MS, GC-MS, and GC-MS/MS—are the most commonly used bioanalytical techniques for identification and quantification of drugs and their metabolites in biological fluids, supporting TDM, pharmacokinetic/pharmacodynamic studies, drug abuse control, and forensic-toxicological analyses.

The development and validation of bioanalytical methods using LC-MS/MS must comply with FDA Bioanalytical Method Validation guidance (2018) and EMA guideline on bioanalytical method validation (2011, revised 2023), covering selectivity, lower limit of quantitation (LLOQ), calibration curve linearity, precision, accuracy, matrix effect, recovery, and stability parameters. These rigorous validation requirements underscore the scientific maturity of LC-MS/MS bioanalysis.

LC-MS/MS also occupies a central role in metabolomics-driven drug discovery. Untargeted metabolomic profiling using UHPLC-HRMS (Orbitrap or Q-TOF) can simultaneously detect thousands of metabolite features in a single injection, generating holistic biochemical fingerprints that illuminate drug mechanism of action, off-target effects, and biomarkers of therapeutic response or toxicity. This application has transformed preclinical and clinical drug development.[8]

GAS CHROMATOGRAPHY–MASS SPECTROMETRY (GC-MS AND GC-MS/MS)

Principles and Instrumentation

Gas chromatography–mass spectrometry (GC-MS) combines the resolving power of capillary GC with the structural specificity and sensitivity of mass spectrometry, making it the premier technique for the identification and quantification of volatile and semi-volatile organic compounds in pharmaceutical samples. The GC separates analytes based on differential partitioning between the stationary phase (a coated fused-silica capillary column, 15–60 m length, 0.1–0.53 mm internal diameter) and the inert carrier gas mobile phase (helium or hydrogen). Analytes elute in order of increasing boiling point modulated by stationary phase polarity interactions.

Interfacing GC with MS is technically more straightforward than LC-MS because GC already handles gaseous analytes at low pressures. The most common GC-MS interface is direct capillary coupling, where the end of the GC column is inserted directly into the ion source of the mass spectrometer through a heated transfer line maintained above the analyte boiling points to prevent condensation. For packed GC columns, jet separators or membrane separators remove the bulk of the carrier gas while preferentially transferring the heavier analyte molecules.

The dominant ionization mode in GC-MS is electron ionization (EI) at 70 eV, which produces a highly reproducible fragmentation pattern—the EI mass spectrum—that serves as a molecular fingerprint for library matching against extensive databases such as the NIST/EPA/NIH Mass Spectral Library (containing >350,000 spectra). This reproducibility across instruments and laboratories, unique to EI-GC-MS, is one of the method's most powerful attributes for compound identification. Chemical ionization (CI), using reagent gases such as methane, isobutane, or ammonia, provides softer ionization producing prominent molecular ion or adduct ion signals when EI fragmentation is excessive.[9]

GC-MS in Residual Solvent Analysis

One of the most critical and standardized applications of GC-MS in pharmaceutical quality control is the determination of residual solvents in drug substances and drug products, as mandated by ICH Q3C guidelines. Class 1 solvents (benzene, carbon tetrachloride, 1,2-dichloroethane, 1,1-dichloroethylene, and 1,1,1-trichloroethane) are associated with unacceptable toxicity and must be limited to 2 ppm; Class 2 solvents have non-genotoxic but toxic potential; Class 3 solvents have low toxic potential. Headspace GC-MS (HS-GC-MS), where volatile solvents are partitioned into the headspace above a heated sample and automatically injected into the GC, is the preferred approach because it eliminates non-volatile matrix interferences and is compatible with both solid and liquid pharmaceutical forms.

The combination of headspace sampling with GC separation and MS detection provides unambiguous identification (via library-matched EI spectra) and accurate quantification (via external or internal standardization) at ppm to sub-ppm levels. Multiple headspace extraction (MHE) or standard addition methods address matrix effects that may affect partition coefficients in complex formulations.

GC-MS/MS in Forensic and Trace-Level Pharmaceutical Analysis

GC coupled to triple quadrupole MS (GC-MS/MS) extends the technique's selectivity by an order of magnitude through MRM acquisition, analogous to LC-MS/MS. GC-MS/MS is especially valuable for the analysis of trace-level contaminants—pesticide residues in herbal medicines, genotoxic alkyl halide impurities in APIs, trace nitrosamines such as NDMA and NDEA in pharmaceutical ingredients—at concentrations in the single-digit ppb to sub-ppb range.

Although GC-MS is still used to assess pharmacokinetics—for example, for fentanyl quantification in the blood of cancer patients—the requirements for analyte volatility and thermal stability narrow the spectrum of pharmaceutically relevant molecules amenable to GC-MS bioanalysis compared to LC-MS/MS, which handles a far broader polarity and molecular weight range. Nevertheless, for volatile analytes, GC-MS provides superior chromatographic resolution and cleaner EI spectra than the LC-MS equivalent.

Two-Dimensional GC (GC×GC-MS)

Comprehensive two-dimensional gas chromatography coupled to MS (GC×GC-MS), employing a cryogenic modulator to focus and re-inject GC column 1 fractions onto a shorter, orthogonally selective GC column 2, dramatically expands the peak capacity of GC analysis—from ~500 peaks in 1D GC to >5,000 structured peaks in GC×GC. Combined with TOF-MS detection, GC×GC-TOF-MS has become a powerful tool for untargeted volatolomics of herbal drug essences, fragrance characterization of pharmaceutical excipients, and comprehensive profiling of complex petrochemical-derived excipients.[10]

HPLC WITH DIODE ARRAY DETECTION (HPLC-DAD)

Principles of Diode Array Detection

The photodiode array (PDA or DAD) detector represents one of the most significant advances in HPLC detection technology. Unlike a single-wavelength UV detector that monitors absorbance at one fixed wavelength, the DAD contains a polychromatic light source (deuterium lamp for UV, tungsten lamp for visible), a flow cell, and an array of typically 1024 individual photodiodes that simultaneously measure absorbance across the entire 190–800 nm spectral range at each instant during the chromatographic run. The result is a three-dimensional data matrix of absorbance as a function of both wavelength and retention time—colloquially termed a chromatographic-spectral landscape.[11]

This three-dimensional data capability confers several analytical advantages unique to DAD over single-wavelength detection: (i) wavelength optimization post-run, permitting selection of the wavelength of maximum absorbance for each compound, enhancing sensitivity; (ii) spectral peak purity assessment, wherein the UV spectrum is compared at the peak front, apex, and tail to detect co-eluting impurities sharing the same retention time but differing spectral profiles—a critical capability for stability-indicating methods; (iii) library-matching of UV spectra to chromophore databases for tentative compound identification; and (iv) dual or multiple wavelength monitoring within a single run for compounds absorbing at different wavelengths.

HPLC-DAD in Stability-Indicating Method Development

Stability-indicating methods (SIMs) are validated analytical procedures capable of accurately quantifying the active pharmaceutical ingredient (API) in the presence of its degradation products, process impurities, excipients, and other formulation components. ICH Q1A(R2) and ICH Q2(R1) mandatorily require specificity demonstration through forced degradation studies, and peak purity analysis by DAD is the cornerstone of specificity verification at the chromatographic level.

HPLC-DAD methods are extensively employed for simultaneous quantification of APIs and multiple related impurities. The method developed and validated for fexofenadine hydrochloride and its related compounds (keto fexofenadine, meta-isomer, methyl ester, and methyl ester of ketofexofenadine) using a Hypersil BDS C-18 column with phosphate buffer-methanol mobile phase demonstrates the ability of HPLC-DAD to simultaneously separate structurally similar compounds and achieve ICH-compliant validation parameters including linearity, accuracy, precision, LOD, and LOQ.

A validated HPLC-DAD method for therapeutic drug monitoring of thiopurine metabolites (thioguanine nucleotides and methylmercaptopurine nucleotides) in pediatric patients with inflammatory bowel disease and acute lymphoblastic leukemia, developed and validated in 2022 according to the most recent ICH guidelines, exemplifies the method's utility in clinical pharmacology and demonstrates linearity, precision, and accuracy suitable for bedside application.

Limitations and Complementarity with MS Detection

Despite its versatility, HPLC-DAD has inherent limitations: it cannot identify compounds lacking

UV chromophores; it cannot provide molecular weight or structural information; spectral peak purity analysis is inherently insensitive to co-eluting compounds with similar UV spectra; and it is less sensitive than MS detection, particularly for trace-level impurities. These limitations make HPLC-DAD and LC-MS highly complementary—DAD provides real-time spectral purity monitoring and cost-effective routine quantification, while LC-MS provides confirmatory identification and ultra-trace quantification.[12]

LIQUID CHROMATOGRAPHY–NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY (LC-NMR)

Principles and Historical Development

Liquid chromatography–nuclear magnetic resonance spectroscopy (LC-NMR), also written as HPLC-NMR, represents the union of arguably the most powerful separation technique (HPLC) with arguably the most information-rich spectroscopic technique for molecular structure determination (NMR). NMR spectroscopy, grounded in the quantum mechanical phenomenon of nuclear spin precession in a magnetic field, provides detailed information about molecular connectivity, stereochemistry, dynamic behaviour, and chemical environment through 1H, 13C, 31P, 19F, and 15N nuclei—a breadth of structural data unmatched by any other technique.

The concept of on-line LC-NMR was first demonstrated by Watanabe and Niki in 1978, but practical implementations for pharmaceutical analysis only emerged in the 1990s following advances in superconducting NMR magnets, cryo-probe technology, and solvent suppression sequences. The technique has since evolved through several operational modes, including on-flow, stop-flow, loop-collection, and the highly sensitive solid-phase extraction (SPE)-NMR (also called loop-storage NMR or LC-SPE-NMR), each offering different trade-offs between throughput, NMR measurement time, and sensitivity.

Operating Modes in LC-NMR

In on-flow LC-NMR, the HPLC eluent continuously flows through the NMR probe cell as the chromatographic separation proceeds in real time. This mode offers the highest throughput and is well-suited for abundant or easily detectable analytes, but the short residence time in the NMR probe limits the number of scans that can be acquired, compromising signal-to-noise ratio for trace components. Solvent signals from non-deuterated HPLC solvents (acetonitrile, methanol, water) present an overwhelming challenge: the powerful solvent signals and faint substance signals cannot be processed by the NMR spectrometer receiver simultaneously without sophisticated suppression methods.[13]

Stop-flow LC-NMR addresses the sensitivity limitation by halting the HPLC pump when a peak of interest is positioned within the NMR probe, permitting extended signal acquisition. This mode is valuable for compounds present at concentrations above ~10–50 µg/mL. Loop-storage or time-slice collection stores chromatographic fractions in capillary loops for subsequent NMR analysis, decoupling the chromatographic timescale from the NMR timescale entirely. The most sensitive approach, LC-SPE-NMR, traps individual chromatographic fractions onto multiple small SPE cartridges, which are then dried (eliminating protonated solvents without requiring deuterated solvents) and eluted with deuterated solvents into the NMR probe, achieving 10–100-fold sensitivity enhancement over on-flow mode.

Pharmaceutical Applications of LC-NMR

LC-NMR is ideally positioned for structural elucidation of pharmaceutical degradation products, synthetic process impurities, and natural product constituents that are either unavailable as authentic standards or present in insufficient quantities for classical isolation-based NMR. The comprehensive review of LC-NMR methods and applications published in the Journal of Separation Science (2025) provides an extensive survey of pharmaceutical and natural product applications, examining the supporting strategies for LC-NMR such as solvent suppression methods, more specialized NMR cell designs, and further hyphenation to mass spectrometry within a single hyphenated platform.

LC-NMR has proven particularly transformative in natural product chemistry, where plant extracts contain dozens to hundreds of structurally related secondary metabolites that are poorly resolved by any single analytical approach. A review published in Sciences in 2021 evaluated the extraordinary technological advancements of LC-NMR for the separation and structural elucidation of unknown compounds in plant-derived mixtures, emphasizing its advantages of high efficiency, rapidity, and small sample amount in natural product analysis where traditional isolation strategies would require large quantities of starting material and laborious chromatographic purification.

The coupling of HPLC with NMR to form triple hyphenated systems—HPLC-DAD-MS-SPE-NMR or LC-MS/NMR—provides orthogonal structural data within a single analytical workflow. A study published in the Journal of Pharmaceutical and Biomedical Analysis (2023) described the separation and identification of a complex flurbiprofen-polyethylene glycol monoester and diester mixture using a hyphenated HPLC-DAD-HRMS/SPE-NMR system, demonstrating the unique capability of such multidimensional platforms for characterizing structurally complex pharmaceutical excipient impurities.

Challenges and Recent Advances

The primary limitations of LC-NMR are its relatively low sensitivity compared to LC-MS, the requirement for solvent suppression, the high capital cost of high-field NMR instruments, and the slower data processing workflow. Recent technological advances substantially mitigate these limitations. Ultra-high-field magnets (600–1000 MHz ^{1}H frequency) provide enhanced signal dispersion and sensitivity. Cryo-probes operating at cryogenic probe coil temperatures dramatically improve signal-to-noise ratio (by approximately 3–4 fold compared to room-temperature probes). Microflow probes and capillary NMR probes extend LC-NMR capability to nanomole quantities of analyte. Additionally, the advent of automated structure elucidation software integrating computer-assisted structure elucidation (CASE) algorithms reduces the expert NMR interpretation time substantially.[14]

CAPILLARY ELECTROPHORESIS–MASS SPECTROMETRY (CE-MS)

Principles of Capillary Electrophoresis

Capillary electrophoresis (CE) is a family of high-efficiency separation techniques that employ narrow-bore (25–100 µm internal diameter) fused-silica capillaries filled with electrolyte buffer to separate analytes driven by an applied high voltage (10–30 kV). CE exploits differences in electrophoretic mobility—a function of ionic charge, molecular size (hydrodynamic radius), and solution viscosity—to resolve analytes at exceptionally high plate counts exceeding 500,000 theoretical plates in capillaries of only 50–100 cm length. CE encompasses several operational modes: capillary zone electrophoresis (CZE), micellar electrokinetic capillary chromatography (MEKC), capillary isoelectric focusing (CIEF), capillary isotachophoresis (CITP), and capillary electrochromatography (CEC).

CE's critical analytical advantages include: minimal sample consumption (nanolitre injection volumes versus microlitre for HPLC), extremely high separation efficiency, compatibility with aqueous non-organic mobile phases (relevant for biological analytes), capacity to separate charged species regardless of polarity, and suitability for the analysis of hydrophilic compounds difficult to retain on reversed-phase HPLC columns. Its primary limitations relative to HPLC are lower loading capacity, shorter path length UV detection (lower sensitivity), and lower reproducibility of migration times due to electroosmotic flow (EOF) variability.

CE-MS Coupling and Instrumentation

Coupling CE to mass spectrometry requires solving the electrochemical interface problem: the CE high-voltage circuit must be maintained while transferring the tiny CE flow (nanolitres per minute) to the mass spectrometer ion source, typically operated at atmospheric pressure via ESI. The dominant interface design employs a coaxial sheath-liquid approach, where a sheath liquid (typically methanol/water/formic acid) is added concentrically around the CE capillary end to provide a stable electrical connection and supplement the CE flow to a level sufficient for stable ESI. Sheath-less ESI interfaces, using either porous-tip or nanospray capillary terminations, eliminate sheath-liquid dilution and ion suppression, improving concentration sensitivity by 10–100-fold—a critical advantage for the nanomolar concentrations typical in CE bioanalysis.

A comprehensive review published in Electrophoresis (2025) provided an in-depth exploration of CE-MS in biomolecular research from 2020 to 2024, confirming that CE-MS has emerged as a versatile and powerful tool facilitating the analysis of various biomolecules including proteins, peptides, oligonucleotides, metabolites, lipids, carbohydrates, and amines, with its numerous advantages evidenced across all CE modes.[15]

Chiral Analysis by CE-MS

Perhaps the most compelling pharmaceutical application of CE-MS is chiral separation and analysis. Enantiomeric drugs may exhibit dramatically different pharmacological activities, metabolic fates, and toxicity profiles. Regulatory authorities require complete chiral characterization of racemic or single-enantiomer drugs. CE achieves chiral resolution through the inclusion of chiral selectors—most commonly cyclodextrins (α-, β-, or γ-cyclodextrin and their chemical derivatives) or antimicrobial glycopeptides—into the background electrolyte, where differential inclusion complex formation with the two enantiomers creates mobility differences exploitable for separation.

A landmark review by Shamsi and Akter published in Molecules (2022) surveyed chiral CE-MS developments and applications from 2011 to 2020, critically examining the challenges of chiral selector incompatibility with ESI-MS (many chiral selectors ionize poorly or cause ion suppression) and describing elegant solutions including partial filling technique, counter-migration techniques, and the use of molecular micelles as MS-compatible chiral selectors. The review concluded that CE-MS is highly promising for chiral analysis of drugs in pharmaceutical development, quality control, pharmacokinetics, and pharmacodynamics research.

A complementary study published in the Chinese Journal of Chromatography (2022) by Chi and Yang reviewed advances in chiral separation and analysis by CE-MS, confirming that drug enantiomers with distinct pharmacological activities and metabolic rates require mandatory enantioselective analysis, and that CE-MS provides a powerful platform for this purpose with recent studies focusing on the development of MS-friendly and highly selective chiral selectors.[16]

CE-MS for Biopharmaceuticals

CE-MS is gaining significant traction in the characterization of biopharmaceuticals—monoclonal antibodies (mAbs), peptides, oligonucleotides, and biosimilars—where its exceptional resolving power for charged molecules and low sample consumption align with the scarce and precious nature of biotherapeutic candidates in early development. Capillary isoelectric focusing coupled to MS (CIEF-MS) enables simultaneous separation and mass characterization of charge variants (deamidation, isomerization, glycoforms) of therapeutic proteins. These charge variants are critical quality attributes (CQAs) under ICH Q6B that require rigorous monitoring throughout the biopharmaceutical development and manufacturing lifecycle.

COUPLED THERMAL ANALYSIS TECHNIQUES

Thermogravimetric Analysis–Mass Spectrometry (TGA-MS)

Thermogravimetric analysis (TGA) is a fundamental thermal analytical technique in which the mass of a sample is continuously monitored as a function of temperature or time under a controlled atmosphere. TGA generates a thermogram that quantitatively depicts mass loss events—attributable to moisture loss, solvent volatilization, decomposition, oxidation, or sublimation—providing crucial information for pharmaceutical characterization including moisture content, residual solvent profiling, thermal stability, decomposition temperature, and polymorphic transitions.[17]

Coupling TGA with mass spectrometry (TGA-MS) dramatically enhances the interpretive power of standalone TGA by enabling real-time identification of the gases evolved during each mass loss event. The TGA-MS coupling combines the features of thermogravimetric analysis with mass spectrometry, where the direct coupling without an intermediate GC separation step offers real-time identification of the gases emitted as a function of temperature, unlike the TGA-FTIR coupling that requires assignment of gas-phase IR absorption bands. In TGA-MS, the evolved gases are transferred from the TGA furnace to the mass spectrometer via a heated quartz inert capillary or fused silica transfer line maintained above the dew point of the evolved species, typically operating at 200–300°C. A quadrupole mass spectrometer operating in scan mode or selective ion monitoring mode detects and characterizes the transferred gases.

Wesolowski and Leyk published a comprehensive review of coupled and simultaneous thermal analysis techniques in the study of pharmaceuticals in Pharmaceutics (2023), describing the design of TG-FTIR, TG-MS, and TG-GC/MS systems and their pharmaceutical applications. Using medicinal substances as examples, the review highlights the key importance of coupled techniques in pharmaceutical technology: they make it possible not only to understand precisely the behaviour of medicinal substances during heating and to identify volatile degradation products, but also to determine the mechanism of thermal decomposition, predict behaviour during manufacture, and determine shelf life and storage conditions.[18]

DSC-FTIR and Other Coupled Thermal Techniques

Differential scanning calorimetry (DSC) measures the heat flow to or from a sample relative to a reference as both are subjected to a controlled temperature programme, detecting endothermic (melting, desolvation) and exothermic (crystallization, decomposition) transitions. Coupling DSC with FTIR microspectroscopy—either as a hybrid instrument or via in situ measurements—enables direct assignment of the thermal transition to a molecular-level structural change, particularly valuable for polymorphism characterization, drug-excipient compatibility studies, and amorphous solid dispersion characterization.

Simultaneous thermal analysis (STA), which applies both TGA and DSC to the same sample in a single instrument, provides complementary information: the TGA identifies when and how much mass is lost, while DSC simultaneously identifies the energetics of the transition (endothermic vs. exothermic). The SDT650 STA instrument (TA Instruments), for example, can operate from ambient to 1200°C and is routinely coupled to evolved gas analysers (Hiden HPR-20 EGA) for pharmaceutical solid-state investigations.[19]

Pyrolysis-GC-MS (Py-GC-MS) extends the thermal approach to structural characterization: instantaneous thermal pyrolysis of polymers or drug-polymer matrices at pre-programmed temperatures generates characteristic fragment patterns that, when separated by GC and identified by MS library matching, permit unambiguous characterization of the polymer component of pharmaceutical coatings, matrix tablets, and biodegradable microspheres.

MULTIDIMENSIONAL AND ADVANCED HYPHENATED PLATFORMS

Comprehensive Two-Dimensional LC (LC×LC)

Comprehensive two-dimensional liquid chromatography (LC×LC) employs two serially coupled HPLC columns with orthogonal separation selectivities—most commonly reversed-phase (RP) coupled to hydrophilic interaction liquid chromatography (HILIC) or normal-phase, ion-exchange, or size-exclusion modes. A switching valve rapidly and sequentially transfers the entire column 1 eluent to column 2 for secondary separation. When column 2 cycle time is short relative to the elution width of column 1 peaks, true 'comprehensive' 2D separation is achieved with a theoretical peak capacity equal to the product of the two individual peak capacities ($n_1 \times n_2$), potentially exceeding 10,000 for pharmaceutical matrices.

LC×LC-MS dramatically reduces false positives in pharmaceutical impurity profiling by resolving co-eluting species that would be reported as single peaks in 1D LC. It has found particular utility in the characterization of monoclonal antibody charge variants, glycoforms, and size variants in biopharmaceutical quality control.

Ion Mobility Spectrometry–Mass Spectrometry (IMS-MS)

Ion mobility spectrometry (IMS) separates ions in the gas phase based on their collisional cross-section (CCS)—a physical parameter related to molecular shape and size. When coupled to MS (IMS-MS or IM-MS), IMS adds a structurally informative ion separation dimension that occurs on the millisecond timescale between the ionization and mass analysis steps, conforming naturally to the existing MS workflow without requiring additional sample preparation or chromatographic time. Travelling wave IMS (TWIMS), differential mobility analysis (DMA), and trapped ion mobility spectrometry (TIMS) are the principal commercial IMS implementations.

In pharmaceutical analysis, IMS-MS is uniquely valuable for differentiating isobaric and isomeric impurities—such as positional isomers of drug candidates that are inseparable by chromatography and indistinguishable by nominal mass MS. The measured CCS value adds a distinctive structural parameter that, combined with accurate mass and MS/MS fragmentation, provides substantially higher confidence in compound identification.

Supercritical Fluid Chromatography–MS (SFC-MS)

Supercritical fluid chromatography (SFC) employs supercritical carbon dioxide ($scCO_2$) as the primary mobile phase, modified with small percentages of organic co-solvents (methanol, ethanol). $scCO_2$ has physical properties intermediate between a gas and a liquid—low viscosity (enabling fast analysis), high diffusivity (improving mass transfer), and tunable solvent strength. SFC-MS is particularly powerful for chiral pharmaceutical analysis, providing rapid enantioseparations on chiral stationary phases with shorter run times than HPLC-based chiral methods. SFC-MS also finds application in lipid analysis, fat-soluble vitamin quantification, and natural product profiling.

Ambient Ionization Mass Spectrometry

Ambient ionization techniques—direct analysis in real time (DART-MS), desorption electrospray ionization (DESI-MS), and rapid evaporation ionization mass spectrometry (REIMS)—directly analyze samples in their native state without sample preparation or chromatographic separation. While these techniques sacrifice the separation component of the hyphenated architecture, they achieve exceptional throughput (seconds per sample) and are increasingly important in pharmaceutical quality control for rapid screening of counterfeits, tablet content uniformity, and real-time process analytical technology (PAT) applications.[20]

REGULATORY CONTEXT AND VALIDATION REQUIREMENTS

ICH Guidelines Relevant to Hyphenated Techniques

The pharmaceutical analytical laboratory operates within a rigorous framework of ICH guidelines that directly mandate the use of hyphenated techniques. ICH Q3A and Q3B establish thresholds for reporting, identification, and qualification of drug substance and drug product impurities (typically 0.05–0.1%), with identification required for any impurity above the threshold, implying the use of spectroscopic hyphenated methods capable of structural characterization. ICH M7 extends these requirements to potentially mutagenic (genotoxic) impurities, setting acceptance limits as low as 1.5 µg/day and mandating sensitive analytical methods—specifically LC-MS/MS—for detection at such trace levels.

ICH Q2(R2)—the revised analytical procedure validation guideline adopted in 2023—addresses method validation for a broader range of modern analytical tools including mass spectrometry-based methods and clarifies validation requirements for complex techniques like LC-MS/MS bioanalytical methods, harmonizing with the FDA and EMA bioanalytical method validation guidance. ICH Q14 on analytical procedure development, adopted in 2023 alongside Q2(R2), promotes analytical procedure development knowledge management (APKM) and supports the implementation of analytical quality by design (AQbD) principles in hyphenated method development.[21]

System Suitability and Method Validation Parameters

All hyphenated analytical methods intended for GMP applications must be validated according to ICH Q2(R2) for the performance characteristics relevant to the intended purpose: specificity/selectivity, linearity, range, accuracy, precision (repeatability, intermediate precision), LOD, LOQ, and robustness. For bioanalytical LC-MS/MS methods, additional parameters required by FDA/EMA guidance include matrix factor (ion suppression/enhancement assessment), incurred sample reanalysis (ISR), and hemolysis/lipemia effects for plasma matrices.

System suitability testing (SST)—the daily verification that the chromatographic system is performing within pre-specified parameters (theoretical plate count, tailing factor, resolution, retention time reproducibility)—must be adapted for hyphenated systems to include detector-specific checks. For LC-MS/MS, SST typically includes monitoring of instrument response (MRM transition signal intensities), mass accuracy (for HRMS platforms), and sensitivity benchmarking against acceptance criteria established during method validation.

GMP Considerations for Hyphenated Instruments

Hyphenated analytical instruments operating in GMP environments require comprehensive instrument qualification (IQ/OQ/PQ) and ongoing performance verification according to USP <1058> (Analytical Instrument Qualification). Data integrity compliance under FDA 21 CFR Part 11 and EU Annex 11 requires that all electronic analytical data generated by hyphenated systems—chromatograms, mass spectra, NMR spectra—be recorded, stored, and retrievable with complete audit trail functionality. Modern hyphenated instrument software platforms (Thermo Fisher Scientific Xcalibur, Waters MassLynx, Bruker DataAnalysis, Agilent MassHunter) incorporate 21 CFR Part 11 compliant features.[22]

ADVANTAGES, LIMITATIONS, AND COMPARATIVE EVALUATION

General Advantages of Hyphenated Techniques

Hyphenated analytical techniques offer several compelling advantages that have driven their near-universal adoption in pharmaceutical laboratories. First, simultaneous separation and detection in a closed, automated system minimizes sample handling, reduces contamination risk, and improves reproducibility compared to classical offline approaches requiring multiple analytical steps. Second, the multi-detector information content dramatically increases analytical certainty—a retention time match alone in HPLC is insufficient for compound identification, but the combination of retention time, molecular mass (MS), MS/MS fragmentation pattern, and UV spectrum from HPLC-DAD-MS provides orthogonal, unambiguous identification.

Third, automation and high throughput are inherent to modern hyphenated systems. Autosampler technology permits unattended analysis of hundreds of samples per day, meeting the throughput demands of pharmaceutical screening and quality control. Fourth, minimal sample volume requirements—particularly for CE-MS (nanolitre injections) and UHPLC-MS/MS (typically 2–10 µL plasma for bioanalysis)—are critical when analyte is scarce (e.g., early drug candidates, precious clinical samples). Fifth, the sensitivity achieved by hyphenated MS-based techniques far exceeds standalone UV or fluorescence detection, enabling detection and quantification at the ppt (parts per trillion) level for some analytes in biological matrices.[23]

Limitations and Challenges

Despite their power, hyphenated techniques present challenges that require careful consideration. Ion suppression in LC-MS—whereby co-eluting matrix components reduce analyte ionization efficiency—is a persistent challenge in complex matrices and requires rigorous method validation including matrix effect assessment and appropriate use of stable isotope-labelled internal standards. For LC-NMR, low sensitivity, solvent suppression requirements, and high instrumentation cost restrict its routine application to structural elucidation tasks rather than routine quantitative analysis. GC-MS is inherently limited to volatile and thermally stable compounds; derivatization is required for thermolabile or polar pharmaceutical analytes. CE-MS coupling efficiency is reduced by the very small injection volumes and relatively unstable electroosmotic flow under varying ionic strength conditions. TGA-MS is a bulk technique unsuited to separated component identification; it provides only evolved gas information and cannot distinguish between surface-bound and interior-located volatile species in solid dosage forms without complementary techniques.[24]

High capital and operational costs represent a significant barrier for smaller pharmaceutical laboratories or resource-limited settings. A modern UHPLC-Q-Orbitrap system may cost USD 300,000–600,000, while a triple quadrupole LC-MS/MS platform for bioanalysis may cost USD 200,000–400,000, exclusive of operating costs (column consumables, high-purity solvents, nitrogen/helium gas, maintenance contracts). Training requirements are also substantial: mass spectrometrists with data interpretation expertise are in high demand and require years of specialist training.

Comparative Summary of Key Hyphenated Techniques

Table 2. Comparative Evaluation of Major Hyphenated Analytical Techniques in Pharmaceutical Analysis

Technique	Sensitivity	Structural Info	Chiral Separation	Sample Types	Relative Cost
LC-MS/MS	Excellent (fg/mL)	Molecular mass + MS/MS	Possible with chiral columns	All matrices	High
UHPLC-HRMS	Excellent	Exact mass + MS^n	Possible	All matrices	Very High
GC-MS	Very Good (pg/mL)	EI library match + MW	With chiral columns	Volatile analytes	Moderate

HPLC-DAD	Good (ng/mL)	UV chromophore only	With chiral columns	Most pharmaceutical	Low
LC-NMR	Low (µg)	Full structural elucidation	With chiral shift reagents	Pure or semi-pure fractions	Very High
CE-MS	Very Good (nM)	Molecular mass + MS/MS	Excellent (CDs)	Biologics, polar molecules	Moderate-High
TGA-MS	Low (EGA)	Evolved gas composition	N/A	Solids, thermally labile	Moderate

EGA = evolved gas analysis; CDs = cyclodextrins; MW = molecular weight.

EMERGING TRENDS AND FUTURE PERSPECTIVES

Miniaturization and Lab-on-Chip Hyphenated Systems

The miniaturization of hyphenated analytical systems toward microfluidic and chip-based platforms represents one of the most actively pursued research frontiers in pharmaceutical analysis. Microchip-based CE-MS systems—integrating microfluidic separation channels, on-chip electrospray emitters, and nanoelectrospray ionization—achieve sub-femtomole detection limits with sample volumes below 100 nL, enabling single-cell metabolomic analysis and drug distribution studies in microscale tissue specimens.[25] Lab-on-a-chip LC-MS systems using micropillar array columns or monolithic stationary phases embedded in silicon or polymer chips achieve ultra-fast HPLC separations compatible with nano-ESI MS, approaching the sensitivity of classical nanoLC-MS/MS in a fraction of the instrument footprint.

High-Resolution Ion Mobility–Mass Spectrometry (HRIMS-MS)

Next-generation high-resolution ion mobility spectrometry platforms—including structures for lossless ion manipulation (SLIM) and the cyclic travelling wave IMS (cTWIMS) introduced by Waters Corporation—achieve resolution powers (Rp) of 200–500 for drift tube IMS compared to conventional TWIMS values of 30–60. This dramatic improvement in IMS resolution makes it possible to distinguish drug metabolites, diastereomers, and conformational isomers that remain unresolved by conventional MS alone. The CCS database for pharmaceutically relevant compounds is rapidly expanding, providing reference values for compound identification analogous to the role of retention index databases in GC-MS.[26]

Artificial Intelligence and Machine Learning in Data Interpretation

The volume and complexity of data generated by modern hyphenated systems—particularly untargeted UHPLC-HRMS and NMR datasets—exceed the processing capacity of traditional manual interpretation. Artificial intelligence (AI) and machine learning (ML) approaches are being rapidly integrated into hyphenated analytical data workflows. Deep learning models trained on large spectral libraries now enable automated structure prediction from MS/MS fragmentation spectra, achieving performance comparable to expert chemists for common pharmaceutical scaffold types. Natural language processing (NLP) and generative AI tools facilitate rapid literature-mining of spectral databases and reference analytical data to support compound identification.

In NMR-based structure elucidation—a historically expert-intensive process—computer-assisted structure elucidation (CASE) algorithms such as ACD/Structure Elucidator and Bruker's NMR data processing AI tools can propose and rank candidate structures from 2D NMR datasets (COSY, HSQC, HMBC, NOESY) in minutes rather than days, dramatically accelerating the characterization of novel degradation products and natural product constituents in LC-SPE-NMR workflows.[27]

Green Analytical Chemistry Perspectives

There is increasing emphasis on the environmental and sustainability credentials of pharmaceutical analytical methods—a philosophy encapsulated in the green analytical chemistry (GAC) movement formalized by the Green Analytical Procedures Index (GAPI) and the Analytical Eco-Scale scoring systems. Hyphenated techniques contribute positively to GAC through miniaturization (reducing solvent and sample consumption), use of greener mobile phase solvents (water, CO_2 in SFC), elimination of derivatization steps, and faster analytical cycles. Ultra-trace detection capability of LC-MS/MS reduces the need for large sample volumes and extensive sample pre-concentration, further reducing the environmental footprint.

A 2025 stability-indicating UHPLC-DAD-MS/MS study for ritlecitinib incorporated GAC assessment using GAPI and the blue applicability grade index (BAGI), demonstrating that method developers are increasingly required to report and optimize the ecological character of proposed analytical procedures—a trend likely to intensify as regulatory agencies formally incorporate GAC considerations into analytical submission requirements.

Process Analytical Technology (PAT)

The FDA's PAT initiative encourages real-time, in-process quality monitoring to replace end-product testing in pharmaceutical manufacturing. Hyphenated spectroscopic techniques—particularly near-infrared (NIR) spectroscopy, Raman spectroscopy, and mass spectrometry—configured for at-line, on-line, or in-line monitoring of critical quality attributes (CQAs) during synthesis, granulation, blending, drying, and coating operations are central to PAT implementation. Ambient ionization MS techniques such as DART-MS and DESI-MS, requiring no sample preparation, are particularly amenable to at-line manufacturing quality control.[28]

SELECTED CASE STUDIES IN PHARMACEUTICAL APPLICATIONS

LC-MS/MS for N-Nitrosamine Impurity Analysis

The discovery of mutagenic N-nitrosamine impurities (NDMA, NDEA) in angiotensin receptor blockers (sartans) in 2018 triggered unprecedented regulatory action and analytical innovation. The development of validated LC-MS/MS methods for the simultaneous quantification of multiple nitrosamines in complex drug matrices at sub-1 ppm levels exemplified the power of hyphenated techniques to respond to emerging pharmaceutical crises. A 2025 study described a comparative evaluation of chromatographic separation and LC-MS/MS application for nitrosamine drug substance-related impurities (NDSRIs) derived from nortriptyline and sertraline, addressing the gap in the scientific literature for validated methods for drug-specific NDSRIs and highlighting the technique's superior selectivity and sensitivity for regulatory compliance.[29]

-SPE-NMR for Natural Product Characterization

The structural characterization of the flavonoid and naphthodianthrone constituents of Hypericum perforatum (St. John's Wort)—one of the most widely used herbal medicines globally—employing on-line HPLC-DAD-NMR-MS provided a paradigmatic demonstration of multi-detector hyphenated analysis for natural product quality control. The complementary structural information from UV spectra, MS molecular masses and fragmentation, and ^{1}H NMR chemical shifts and coupling constants enabled unambiguous structural assignment of multiple related phloroglucinol derivatives without the need for laborious isolation and classical NMR analysis of each constituent individually.[30]

CE-MS for Biopharmaceutical Charge Variant Profiling

Therapeutic monoclonal antibodies (mAbs) are inherently heterogeneous, existing as populations of charge variants arising from post-translational modifications including C-terminal lysine clipping, N-terminal pyroglutamate formation, deamidation of asparagine residues, and oxidation of methionine residues. CE combined with UV and MS detection is now the industry-standard approach for charge variant profiling. Capillary isoelectric focusing (CIEF) and imaged CIEF (iCIEF) with UV detection characterize the isoelectric point distribution of charge variants. CE-MS adds the structural dimension of mass characterization to each resolved charge variant, enabling identification of the specific post-translational modification responsible for the charge shift.[31]

TGA-M S for Polymorphic and Solvate Characterization

The correct solid-state form of a drug substance—polymorph, hydrate, solvate, or amorphous form—critically influences solubility, dissolution rate, chemical stability, and ultimately bioavailability. TGA-MS is an irreplaceable tool for unambiguous identification of hydrates and solvates. The MS detection of water (m/z 18), methanol (m/z 32), ethanol (m/z 46), or other solvent molecules evolved during specific TGA mass loss events—combined with their characteristic temperatures and event energetics from simultaneous DSC—provides unambiguous confirmation of the solvate type and stoichiometry, information critical for ICH Q6A solid-state characterization requirements.[32]

CONCLUSION

Hyphenated analytical techniques have irrevocably transformed pharmaceutical analysis, providing capabilities that no single analytical method can match. From the femtogram-level bioanalytical precision of LC-MS/MS triple quadrupole systems to the comprehensive structural elucidation power of LC-SPE-NMR at nanomole quantities, from the volatolomic breadth of GC×GC-TOF-MS to the orthogonal chiral resolution of CE-MS with molecular ionization-compatible cyclodextrin selectors, hyphenated systems address pharmaceutical analytical challenges at every stage of the drug development lifecycle—discovery, preclinical development, clinical development, manufacturing quality control, and post-market surveillance.

The regulatory imperative established through ICH guidelines Q3A/B, M7, Q1A, Q2(R2), and Q14 effectively mandates the use of structurally informative hyphenated techniques for pharmaceutical registration submissions, driving broad adoption across the global pharmaceutical industry. Simultaneously, advances in instrument technology—particularly ultra-high-resolution

Orbitrap mass spectrometry, cryo-probe NMR, sheath-less CE-MS interfaces, and miniaturized chip-based separation systems—continually expand the sensitivity, selectivity, and applicability boundaries of these techniques.

The future of pharmaceutical analysis lies in intelligent integration: multidimensional separation platforms coupled to multiple orthogonal detectors, guided by AI-assisted data interpretation workflows, operating within continuous manufacturing environments enabled by PAT-compatible real-time hyphenated monitoring. The pharmaceutical analyst of the future will need to navigate this landscape with deep understanding of both the physicochemical principles underlying each hyphenated technique and the computational tools required to extract meaning from the rich, multidimensional data they generate. This review provides a foundational framework for that understanding, grounded in the current state of the art as evidenced by the contemporary literature.

REFERENCES

1. Khalikova MA, Rambousek L, Kubíčková A, Janeba Z, Tůma P, Nováková L. What is the role of current mass spectrometry in pharmaceutical analysis? Mass Spectrometry Reviews. 2024 May;43(3):560-609. DOI: 10.1002/mas.21858
2. Wesolowski M, Leyk E. Coupled and simultaneous thermal analysis techniques in the study of pharmaceuticals. Pharmaceutics. 2023 Jun;15(6):1596. DOI: 10.3390/pharmaceutics15061596
3. Shamsi SA, Akter F. Capillary electrophoresis mass spectrometry: developments and applications for enantioselective analysis from 2011–2020. Molecules. 2022 Jun 27;27(13):4126. DOI: 10.3390/molecules27134126
4. Chi Z, Yang L. Advances in chiral separation and analysis by capillary electrophoresis-mass spectrometry. Chinese Journal of Chromatography. 2022 Jun;40(6):509-519. DOI: 10.3724/SP.J.1123.2021.11006
5. Gebretsadik T, Linert W, Thomas M, Berhanu T, Frew R. LC–NMR for natural product analysis: a journey. Sciences. 2021;3(1):6. DOI: 10.3390/sci3010006
6. Losacco GL, Cohen RD, DaSilva JO, Haidar Ahmad IA, Sherer EC, Mangion I, et al. Deuterated modifiers in sub/supercritical fluid chromatography for streamlined NMR structure elucidation. Analytical Chemistry. 2022;94(35):12176-12184. DOI: 10.1021/acs.analchem.2c02623
7. Sahu A, Balhara A, Raju N, Singh VK, Sahu PK, Panda BP. Characterization of degradation products of celiprolol hydrochloride using hyphenated mass and NMR techniques. Journal of Pharmaceutical and Biomedical Analysis. 2021;197:113953. DOI: 10.1016/j.jpba.2021.113953
8. Sharp TR, Marquez BL. Hyphenated methods. In: Wilson ID, editor. Comprehensive Analytical Chemistry. Amsterdam: Elsevier; 2006. p. 1-60.
9. Guillarme D, Ruta J, Rudaz S, Veuthey JL. New trends in fast and high-resolution liquid chromatography: a critical comparison of existing approaches. Analytical and Bioanalytical Chemistry. 2010;397(3):1069–1082. DOI: 10.1007/s00216-009-3305-x

10. Dams R, Huestis MA, Lambert WE, Murphy CM. Matrix effect in bio-analytical methods: when is it a problem and how to solve it? Journal of the American Society for Mass Spectrometry. 2003;14(10):1130–1135. DOI: 10.1016/S1044-0305(03)00416-X
11. Makarov A. Electrostatic axially harmonic orbital trapping: a high-performance technique of mass analysis. Analytical Chemistry. 2000;72(6):1156–1162. DOI: 10.1021/ac991131p
12. Breitling R, Pitt AR, Barrett MP. Precision mapping of the metabolome. Trends in Biotechnology. 2006;24(12):543–548. DOI: 10.1016/j.tibtech.2006.10.006
13. Majors RE, Lough WJ. HPLC method validation. LC-GC North America. 2019;37(8):526–532.
14. Kitson FG, Larsen BS, McEwen CN. Gas chromatography and mass spectrometry: a practical guide. San Diego: Academic Press; 1996. p. 1–341.
15. Gergov M, Mäkinen S, Ojanperä I, Vuori E. Simultaneous screening and quantification of 18 opioids in urine and blood by liquid chromatography-electrospray-tandem mass spectrometry. Forensic Science International. 2001;121(1-2):108–115. DOI: 10.1016/S0379-0738(01)00461-3
16. International Council for Harmonisation. ICH Q1A(R2): Stability testing of new drug substances and products. Geneva: ICH; 2003. Available from: https://www.ich.org/page/quality-guidelines
17. Holčapek M, Jirásko R, Lísa M. Basic rules for the interpretation of atmospheric pressure ionization mass spectra of small molecules. Journal of Chromatography A. 2010;1217(25):3908–3921. DOI: 10.1016/j.chroma.2010.02.049
18. Albert K, editor. On-line LC-NMR and related techniques. Chichester: Wiley; 2002. p. 1–304.
19. Haines PJ. Thermal methods of analysis: principles, applications and problems. London: Blackie Academic & Professional; 1995. p. 1–286.
20. Monge ME, Harris GA, Dwivedi P, Fernández FM. Mass spectrometry: recent advances in direct open air surface sampling/ionization. Chemical Reviews. 2013;113(4):2269–2308. DOI: 10.1021/cr300309q
21. International Council for Harmonisation. ICH Q2(R2)/Q14: Analytical procedure development and revision of Q2(R1) analytical validation. Geneva: ICH; 2023. Available from: https://www.ich.org/page/quality-guidelines
22. United States Pharmacopeia. <1058> Analytical instrument qualification. In: USP-NF. Rockville: USP; 2021. Available from: https://www.usp.org
23. Rossi DT, Sinz MW, editors. Mass spectrometry in drug discovery. New York: Marcel Dekker; 2002. p. 1–500.
24. Skoog DA, Holler FJ, Crouch SR. Principles of instrumental analysis. 7th ed. Boston: Cengage Learning; 2018. p. 1–992.
25. Nge PN, Rogers CI, Woolley AT. Advances in microfluidic materials, functions, integration, and applications. Chemical Reviews. 2013;113(4):2550–2583. DOI: 10.1021/cr300337x

26. May JC, McLean JA. Ion mobility-mass spectrometry: time-dispersive instrumentation. Analytical Chemistry. 2015;87(3):1422–1436. DOI: 10.1021/ac504720m
27. Elyashberg M, Williams A. Computer-based structure elucidation from spectral data: the art of solving problems. Berlin: Springer; 2015. p. 1–454.
28. US Food and Drug Administration. Guidance for industry: PAT — a framework for innovative pharmaceutical development, manufacturing, and quality assurance. Rockville: FDA; 2004. Available from: https://www.fda.gov/media/71012/download
29. Alqahtani MA, Alqahtani MS, Alshammari TM. Comparative evaluation of chromatographic separation and LC-MS/MS application for nitrosamine drug substance-related impurities from nortriptyline and sertraline. Journal of Pharmaceutical and Biomedical Analysis. 2025; 244:116115. DOI: 10.1016/j.jpba.2024.116115
30. Tatsis EC, Boeren S, Exarchou V, Troganis AN, Vervoort J, Gerothanassis IP. Identification of the major constituents of Hypericum perforatum by LC/SPE/NMR and/or LC/MS. Phytochemistry. 2007;68(3):383–393. DOI: 10.1016/j.phytochem.2006.11.026
31. Füssl F, Scheffler K, Farrell A, Standard E, Bones J, Cook K. Comprehensive characterisation of the heterogeneity of adalimumab charge variants by middle-up LC-MS analysis with Fc/2 and Fab fragments. Journal of Chromatography B. 2019;1109:162–170. DOI: 10.1016/j.jchromb.2019.01.031
32. Brittain HG, editor. Polymorphism in pharmaceutical solids. 2nd ed. New York: Informa Healthcare; 2009. p. 1–613.

HOW TO CITE: Arunlal V.B.*, Layana Valsan, Hyphenated Analytical Techniques in Pharmaceutical Analysis: Principles, Instrumentation and Applications, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 6, 724-746. https://doi.org/ 10.5281/zenodo.20526442